Norwalk Hospital FastCare to open clinic inside Fairfield, Conn. Stop & Shop
PURCHASE, N.Y. — Grocer Stop & Shop has joined with Norwalk Hospital FastCare to introduce a new in-store health clinic in Fairfield, Conn.
The clinic will have its official opening on May 20 when Stop & Shop management will be joined by Fairfield first selectman Michael Tetreau and Norwalk Hospital VP business development Michael Marks at a ribbon-cutting ceremony.
"For many years our pharmacists have been strong health resources in our stores by providing information and offering flu clinics. This new partnership with Norwalk Hospital FastCare will expand the health and wellness resources we are able to offer to our customers and provide them with an alternative choice for those needing medical treatment," said Arlene Putterman, public and community relations manager, Stop & Shop New York Metro Division. "This concept increases accessibility to health care at a low, set cost and adds value for our customers."
NYT: Pfizer testifies before British Parliament on AstraZeneca deal
LONDON — Pfizer testified before British Parliament Tuesday regarding its proposed offer to acquire AstraZeneca, the New York Times reported. According to the report, British lawmakers challenged Ian Read, Pfizer CEO, on the company’s commitment to keep jobs in the United Kingdom.
In response, Pfizer committed to keep at least 20% of its combined research-and-development teams in Britain and would follow through on completing a center in Cambridge, England that AstraZeneca has started. Beyond that, Pfizer could make no guarantees, Read said.
The report also suggested Pfizer may be willing to raise the stakes with a higher offer in its proposed acquisition of AstraZeneca, asking AstraZeneca executives to help draft an acceptable deal.
FDA accepts Teva’s sNDA for pediatric QNASL
JERUSALEM — Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company’s supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.
QNASL, a waterless intranasal corticosteroid spray, is currently available to treat patients 12 years of age and older who show symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the company notes.
“We are very pleased the FDA has accepted for review the sNDA for QNASL. If the FDA approves the new indication for QNASL, it will become the first waterless HFA nasal allergy treatment approved for patients as young as 4 years of age,” said Tushar Shah, M.D., SVP at Teva Global Respiratory Research and Development. “The low-dose formulation demonstrates our commitment to the development of innovative treatment options for all patients with respiratory conditions, including nasal allergies.”